Detailed Information on Publication Record
2024
Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology
AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ et. al.Basic information
Original name
Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology
Authors
AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ, Petr MORAVČÍK, Jan HLAVSA, Lukáš MORÁŇ, Riza Can CAKMAKCI, Peter STAŇO, Vladimír PROCHÁZKA, Zdeněk KALA, Jan TRNKA and Petr VAŇHARA
Edition
PANCREAS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0885-3177
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30400 3.4 Medical biotechnology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.900 in 2022
Organization unit
Faculty of Medicine
UT WoS
999
Tags
International impact, Reviewed
Změněno: 19/8/2024 13:00, Mgr. Tereza Miškechová
Abstract
V originále
Pancreas is a vital gland of gastro-intestinal system with exocrine and endocrine secretory functions, interweaved into essential metabolic circuitries of the human body. Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal malignancies, with a five-year survival rate of 11%. This poor prognosis is primarily attributed to the absence of early symptoms, rapid metastatic dissemination, and the limited efficacy of current therapeutic interventions. Despite recent advancements in understanding the etiopathogenesis and treatment of PDAC, there remains a pressing need for improved individualized models, the identification of novel molecular targets, and the development of unbiased predictors of disease progression. Here we aim to explore the concept of precision medicine utilizing three-dimensional, patient-specific cellular models of pancreatic tumors and discuss their potential applications in uncovering novel druggable molecular targets and predicting clinical parameters for individual patients.
Links
MUNI/A/1558/2023, interní kód MU |
| ||
MUNI/A/1598/2023, interní kód MU |
| ||
NU23-08-00241, research and development project |
|